RCS - Allergy Therapeutics - Allergy Therapeutics presents findings at EAACI

Allergy TherapeuticsAnnouncement

13/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250613:nRSM6844Ma&default-theme=true

RNS Number : 6844M  Allergy Therapeutics PLC  13 June 2025

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", or the "Group")

 

Allergy Therapeutics presents key scientific findings from research portfolio
at EAACI 2025

 

13 June 2025: Allergy Therapeutics (AIM: AGY), the fully integrated commercial
biotechnology company specialising in allergy immunotherapies, today announces
that it will share key scientific findings from across its research portfolio
at the European Academy of Allergy and Clinical Immunology (EAACI) Congress
(https://eaaci.org/events_congress/eaaci-congress-2025/) , taking place from
today until 16 June in Glasgow, United Kingdom.

 

The EAACI Congress is the world's largest scientific conference specialising
in the field of allergy and clinical immunology and the flagship meeting of
the European Academy of Allergy and Clinical Immunology. The Academy is an
association of more than 16,000 clinicians, researchers and allied health
professionals from 124 countries, dedicated to improving the health of people
affected by allergic diseases.

 

Among its posters being presented, Allergy Therapeutics will share:

 * Preliminary clinical proof of concept for the Group's novel immunomodulating
peanut allergy vaccine candidate demonstrated in peanut-allergic patients
after three injection days, four weeks apart at two low cumulative doses. The
peanut allergy vaccine candidate, currently at the final cohort stage of the
first-in-human Phase I/IIa PROTECT trial, shows a benign safety profile in
healthy subjects and peanut allergic patients. Moreover, it has demonstrated a
strong dose-dependent reduction in skin-prick-test wheal size at low
cumulative doses, accompanied by concordant biomarker changes supporting its
hypoallergic mode of action in combination with early signs of a potent,
clinically meaningful immune response.

 * Data showing a statistically significant, clinically relevant and consistent
improvement in Rhinoconjunctivitis Quality of Life Questionnaire score and for
all corresponding quality of life subdomains in patients with allergic
rhinitis and/or rhinoconjunctivitis treated with Grass MATA MPL, the Group's
short-course subcutaneous immunotherapy candidate, compared with two
registered grass sublingual immunotherapy products.

 * Biomarker findings from the pivotal Phase III G306 trial demonstrating that
Grass MATA MPL induces a tolerogenic immune signature, including elevated
grass-specific IgG₄ and IgA, the induction of functional blocking
antibodies, strong reduction of the allergic response pathway by suppressing
basophil activity and a shift in T-cell populations from Th2 to Th1 and
regulatory T cells, in grass-allergic patients.

 

Furthermore, Allergy Therapeutics will host a symposium on Friday, 13 June,
16:30-17:30 BST, chaired by Dr. Montserrat Alvaro, Paediatric Allergist,
Paediatric Allergology and Clinical Immunology Department, Hospital Sant Joan
de Déu, Barcelona, Spain. The symposium will feature expert perspectives on
the evolving treatment landscape for peanut allergy, including clinical and
regulatory considerations, and a deeper dive into the results of the Group's
PROTECT trial, in addition to an overview of its short course Grass MATA MPL
immunotherapy designed to address the symptoms of grass allergy.

 

"We are excited to engage with the global allergy and immunology community at
EAACI 2025, sharing the latest advancements from our pipeline," said Manuel
Llobet, Chief Executive Officer of Allergy Therapeutics. "The preliminary
clinical proof of concept for our peanut allergy vaccine candidate and the
positive quality of life findings from our Grass MATA MPL programme highlight
the potential of our pipeline to transform patient care. These developments
provide strong confidence in the potential for expansion of our VLP platform
in food allergy and beyond, and reflect our dedication to delivering
effective, short-course treatments that address the underlying causes of
allergic disease and, ultimately, transform patients' lives."

 

The full list of Allergy Therapeutics-sponsored abstracts accepted for
presentation is available on the Group's website.

 

No new material price-sensitive information is expected to be disclosed at the
EAACI Congress.

 

 Allergy Therapeutics' Symposium

 Friday, 13 June; 16:30-17:30 (BST)
 Introduction                                                                    Our commitment to patients

 Chair: Dr. Montserrat Alvaro, Paediatric Allergist, Paediatri Allergology and
 Clinical Immunology Department, Hospital Sant Joan de Déu, Barcelona, Spain
 Speaker                                                                         State-ot-the-art evidence

 Professor Lawrence DuBuske, Clinical Professor Medicine, George Washing
 University School of Medicine, Washington, DC, United States
 Speaker                                                                         Changes in the peanut allergy treatment paradigm

 Dr. Wayne Shreffler, Division Chief, Pediatric Allergy and Immunology, Mass
 General Hospital for Children, Boston, United States
 All Speakers                                                                    Q&A session

 

 

- ENDS -

 

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash / Giles Balleny / Seamus Fricker

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries in nine major European countries and via distribution agreements
in an additional ten countries. For more information, please see
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFZGMVMZGGKZZ